Development
Alnylam Pharmaceuticals, Inc.
ALNY
$401.80
$9.562.44%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -440.24M | -509.87M | -1.06B | -1.06B | -1.13B |
| Total Depreciation and Amortization | 97.03M | 97.94M | 95.06M | 91.85M | 85.55M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 436.61M | 423.60M | 526.33M | 498.24M | 539.89M |
| Change in Net Operating Assets | 10.76M | -9.71M | -30.58M | -61.73M | -35.55M |
| Cash from Operations | 104.16M | 1.97M | -472.72M | -536.56M | -541.27M |
| Capital Expenditure | -62.21M | -68.54M | -67.96M | -68.09M | -72.06M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -274.14M | -167.07M | 157.01M | 308.65M | 241.41M |
| Cash from Investing | -336.35M | -235.61M | 89.05M | 240.56M | 169.35M |
| Total Debt Issued | -- | -777.00K | 1.02B | 1.02B | 1.02B |
| Total Debt Repaid | -- | 0.00 | -880.72M | -880.72M | -880.72M |
| Issuance of Common Stock | 147.46M | 173.28M | 301.50M | 274.61M | 259.36M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 24.67M | 23.83M | 23.33M | 27.17M | 31.00M |
| Cash from Financing | 172.13M | 196.34M | 460.23M | 437.17M | 425.75M |
| Foreign Exchange rate Adjustments | 6.39M | -2.89M | 5.69M | -3.02M | -7.43M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -53.67M | -40.18M | 82.24M | 138.15M | 46.40M |